BOSTON, Nov. 18, 2015 /PRNewswire/ -- Frank Condella, CEO of Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or "the Company"), will present at the 27th Annual Piper Jaffray Healthcare Conference as follows:
The webcast presentation will be archived for 90 days via the aforementioned URLs.
The Company recently announced three new product candidates that utilize its proprietary multi-segment intra-vaginal ring (IVR): JNP-0101, an oxybutynin IVR for the treatment of overactive bladder; JNP-0201, a combination IVR delivering estrogen and progesterone for hormone replacement therapy (HRT); and, JNP-0301, a progesterone IVR for the prevention of preterm birth.
The new IVR product candidates complement COL-1077, Juniper's sustained-release 10% lidocaine bioadhesive gel intended for the treatment of gynecologic procedure-related pain. A Phase 2b trial is currently enrolling female patients and results from this clinical trial are expected in mid-2016.
These development programs are supported by strong revenue and cash flow from the Company's CRINONE® (progesterone gel) franchise and UK-based pharmaceutical service business.
About Juniper Pharmaceuticals Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women's health. Juniper has a commercial product, CRINONE® 8% (progesterone gel), which is marketed by Allergan, Inc. in the U.S. and by Merck KGaA, Darmstadt, Germany, in over 90 countries worldwide. The Company is advancing a pipeline of proprietary drug candidates leveraging novel delivery technologies. Please visit www.juniperpharma.com for more information.
Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.
CRINONE® is a registered trademark of Allergan, Inc. in the U.S. and of Merck KGaA, Darmstadt, Germany, outside the U.S.
Forward Looking Statements Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This communication contains forward-looking statements, which statements are usually indicated by the words "may," "will," "plans," "believes," "expects," "anticipates," "potential," "should," or similar expressions, and which are generally not historical in nature. These include all statements relating to expected Juniper's product candidates, their development, and the timing thereof. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management's current expectations and Juniper Pharmaceuticals does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law. For a discussion of certain risks and uncertainties associated with Juniper Pharmaceuticals' forward-looking statements, please review the Company's reports filed with the SEC, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2014 and 10-Q for the period ended September 30, 2015.
Amy Raskopf Director, Corporate Communications Juniper Pharmaceuticals (917) 673-5775 firstname.lastname@example.org
Follow us on LinkedIn
SOURCE Juniper Pharmaceuticals, Inc.